Rituximab
- PMID: 21918268
- DOI: 10.1007/s13312-011-0098-6
Rituximab
Abstract
Rituximab is a chimeric mouse-human monoclonal antibody against the CD 20 antigen on the surface of B lymphocytes. It binds to CD20 and causes B cell death by antibody dependant cell-mediated cytotoxicity, complement mediated cytotoxicity and apoptosis. It leads to rapid and sustained depletion of B cells. It is licensed for use in adults with CD20 positive B-cell lymphoma and rheumatoid arthritis. In children, it has been used in a variety of off-label indications with promising results. It has proved useful as salvage therapy in relapsed refractory non-Hodgkins lymphoma and leukemia, and in hematological conditions including chronic immune thrombocytopenic purpura, hemophilia with inhibitors, and autoimmune hemolytic anemia. It has also proved effective in autoimmune conditions like primary systemic vasculitis and systemic lupus erythematosis. Nephrotic syndrome and opsoclonus-myoclonus syndrome are among the emerging indications for rituximab. In solid organ transplantation, rituximab is useful in the prevention and treatment of acute and chronic rejection as well as in post transplantation lymphoproliferative disease. Toxicity includes acute infusion reactions, susceptibility to bacterial infections, and reactivation of viral infections.
Comment in
-
Rituximab usage in children: a double edged sword.Indian Pediatr. 2012 Apr;49(4):335-6. Indian Pediatr. 2012. PMID: 22565086 No abstract available.
-
Is rituximab approved in pediatric non Hodgkin lymphoma?Indian Pediatr. 2012 May;49(5):419-20. Indian Pediatr. 2012. PMID: 22700674 No abstract available.
Similar articles
-
A review of rituximab in cutaneous medicine.Dermatol Online J. 2006 Jan 27;12(1):3. Dermatol Online J. 2006. PMID: 16638371 Review.
-
Myocardial infarction after rituximab treatment for rheumatoid arthritis: Is there a link?Curr Pharm Des. 2014;20(4):496-9. doi: 10.2174/13816128113199990386. Curr Pharm Des. 2014. PMID: 23565629 Review.
-
Rituximab: current status as therapy for malignant and benign hematologic disorders.BioDrugs. 2012 Apr 1;26(2):71-82. doi: 10.2165/11599500-000000000-00000. BioDrugs. 2012. PMID: 22339395 Review.
-
Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.Annu Rev Med. 2004;55:477-503. doi: 10.1146/annurev.med.55.091902.104249. Annu Rev Med. 2004. PMID: 14746532 Review.
-
Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature.Rheumatol Int. 2013 Nov;33(11):2927-30. doi: 10.1007/s00296-012-2581-3. Epub 2012 Nov 8. Rheumatol Int. 2013. PMID: 23135613 Review.
Cited by
-
A successful treatment of juvenile idiopathic arthritis with rituximab: A report of two cases.Eur J Rheumatol. 2014 Dec;1(4):164-166. doi: 10.5152/eurjrheumatol.2014.140049. Epub 2014 Dec 1. Eur J Rheumatol. 2014. PMID: 27708906 Free PMC article.
-
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD014544. doi: 10.1002/14651858.CD014544.pub2. Cochrane Database Syst Rev. 2024. PMID: 38411279 Free PMC article. Review.
-
A Rare Case of Opsoclonus Myoclonus Ataxia Syndrome Post Viral Illness.Cureus. 2023 Jun 14;15(6):e40396. doi: 10.7759/cureus.40396. eCollection 2023 Jun. Cureus. 2023. PMID: 37456490 Free PMC article.
-
The development and assessment of biological treatments for children.Br J Clin Pharmacol. 2015 Mar;79(3):379-94. doi: 10.1111/bcp.12406. Br J Clin Pharmacol. 2015. PMID: 24750505 Free PMC article. Review.
-
Triptolide regulates neutrophil function through the Hippo signaling pathway to alleviate rheumatoid arthritis disease progression.J Transl Autoimmun. 2024 May 3;8:100242. doi: 10.1016/j.jtauto.2024.100242. eCollection 2024 Jun. J Transl Autoimmun. 2024. PMID: 38765902 Free PMC article.